Anzeige
Mehr »
Login
Sonntag, 20.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Gold auf 4.000 USD? Goldman Sachs sagen Ja - und bei Forge sitzt der Ex-CFO von Newmont mit am Tisch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UHG | ISIN: US7389201077 | Ticker-Symbol:
NASDAQ
17.04.25
17:23 Uhr
0,540 US-Dollar
-0,010
-1,82 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASPIRE BIOPHARMA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ASPIRE BIOPHARMA HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ASPIRE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln
FrAspire Biopharma Holdings, Inc. - 8-K, Current Report2
MoAspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17169HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery...
► Artikel lesen
11.04.Aspire Biopharma beginnt mit der Produktion von Pre-Workout-Nahrungsergänzungsmitteln-
11.04.Aspire Biopharma starts production of pre-workout supplement2
11.04.Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement155Plans to conduct consumer and safety testing during second quarter 2025Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial productionSingle...
► Artikel lesen
09.04.Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation200One clinical trial site activatedPatient enrollment expected in AprilTrial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin productAspire anticipates...
► Artikel lesen
09.04.Aspire Biopharma Holdings, Inc. - S-1, General form for registration of securities4
07.04.Aspire Biopharma Holdings, Inc. - 10-K, Annual Report1
31.03.Aspire Biopharma Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
20.03.Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin205Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submissionCompany expects to commence bioavailability study in April 2025Aspire intends...
► Artikel lesen
13.03.Aspire Biopharma treibt Patentanmeldungen für Arzneimittelverabreichungstechnologie voran5
13.03.Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform216HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug...
► Artikel lesen
11.03.SCD Media, LLC: An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation177New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual...
► Artikel lesen
03.03.Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement206New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout marketDesert Stream Inc., a well-established nutritional and supplement manufacturer of...
► Artikel lesen
25.02.Aspire Biopharma advances to phase 1 clinical trial for aspirin product2
25.02.Aspire Biopharma startet Phase-1-Studie für Aspirin-Produkt3
25.02.Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin354Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the next development step with Phase 1clinical trial expected...
► Artikel lesen
21.02.Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement523NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology...
► Artikel lesen
20.02.Aspire Biopharma Holdings, Inc. - 8-K, Current Report-
20.02.Aspire Biopharma announces public listing on Nasdaq2
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1